Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13970334 | 0.82 | CHRNB2 (0.55) | CHRNB2CHRNA4RECQLCHRNA7ALDH1A1 | |
| SCHEMBL10028665 | 0.81 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7ALDH1A1LMNA | |
| SCHEMBL13949621 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNA4RECQLCHRNA7ALDH1A1 | |
| SCHEMBL16627431 | 0.80 | CHRNB2 (0.77) | CHRNB2CHRNA4CHRNA7ALDH1A1LMNA | |
| SCHEMBL153688 | 0.80 | CARM1 (0.58) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL9827841 | 0.79 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA7ALDH1A1LMNA | |
| SCHEMBL4862940 | 0.79 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA7ALDH1A1LMNA | |
| SCHEMBL14276859 | 0.79 | RECQL (0.64) | CHRNB2CHRNA4RECQLALDH1A1LMNA | |
| SCHEMBL6674571 | 0.78 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1LMNA | |
| SCHEMBL31044635 | 0.78 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138173-B2 | Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138173-B2 | Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090069299-A1 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069299-A1 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-5138062-A | Tranquilizers | PHILIP MORRIS INCORPORATED | 1992-08-11 | — | — | US | disclosed |
| US-5015741-A | Insecticides, aphidicides, psychological disorders, sedatives or tranquilizers | PHILIP MORRIS INCORPORATED (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0421762-A1 | Novel nicotine analogs and method | Philip Morris Products Inc. (US) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069299-A1 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods | IL4, IL2, IL5 | CHRNB2 3990/4885CHRNA4 1670/4885RECQL 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.